Description
Background:
Romiplostim (NPlate) is a fusion protein analog of thrombopoietin, a hormone that regulates platelet
production. Romiplostim is an Fc-peptide fusion protein (peptibody) that signals and activates intracellular
transcriptional pathways via the TPO receptor (also known as cMpl) to increase platelet production. The
peptibody molecule is comprised of a human immunoglobulin IgG1 Fc domain, with each single-chain
subunit covalently linked at the C-terminus to a peptide chain containing 2 TPO receptor-binding domains.
Romiplostim has no amino acid sequence homology to endogenous TPO. In pre-clinical and clinical trials
no anti-romiplostim antibodies cross reacted with endogenous TPO. Romiplostim is indicated for adult
chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory to other
treatments (e.g. corticosteroids, immunoglobulins).
Intended Use:
For Estimation of Remtolumab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!